Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body

Gallbladder Neoplasms, Cholangiocarcinoma

Uterine Cervical Neoplasms

Lung Neoplasms

Pancreatic Neoplasms

CLDN18.2 Positive

Pancreatic Neoplasms

Breast Neoplasms

Lung Neoplasms

Melanoma, Cutaneous Malignant

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

Pancreatic Neoplasms

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Metastatic Pancreatic Ductal Adenocarcinoma

Anal Cancer Metastatic

GastroEsophageal Cancer

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

Pancreatic Neoplasms

Triple Negative Breast Neoplasms

Pancreatic Neoplasms

Clinical Trials

MK-3475A-C18

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

CATPCC-01

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

ARC-8

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

SUPRAME

TroFuse-011

MK-3475-01G

MK-2870-010

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

GOBLET

A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers

MK-3475-01A

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

Saltikva for Metastatic Pancreatic Cancer